Company News: GlaxoSmithKline

Share this article:
GlaxoSmithKline dedicated a new $300,000 production facility at its Nashik site in India to the manufacture of albendazole as part of the World Health Organization's anti-lymphatic filariasis program. The plant will produce 300 million treatments of the drug per year. Lymphatic filariasis, or elephantitis, is a tropical parasitic infection spread by mosquitoes and causing grotesque, painful swelling of the limbs, breasts and genitals. An estimated 120 million people in 83 countries are currently infected.
Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.